Table 2.
Univariable and multivariable Cox regression analyses for progression-free survival of melanoma patients and CAF parameters by cell counts
| Variable (LO/HI) | Anti-PD-1 PFS | |||||
|---|---|---|---|---|---|---|
| Univariable analysis | Multivariablea analysis per variable | Multivariablea analysis with Thy1, SMA, FAP | ||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Thy1+/total | 2.18 (1.17–3.81) | 0.016 | 2.34 (1.21–4.28) | 0.013 | 1.90 (0.98–3.48) | 0.058 |
| SMA+/Thy1+ | 0.55 (0.32–0.97) | 0.038 | 0.55 (0.32–0.99) | 0.048 | 0.71 (0.40–1.31) | 0.26 |
| FAP+/Thy1+ | 1.77 (1.11–2.89) | 0.017 | 2.08 (1.28–3.44) | 0.0030 | 1.79 (1.06–3.04) | 0.031 |
Abbreviations: CAF cancer-associated fibroblast, CI confidence interval, HI high, HR hazard ratio, LO low, PFS progression-free survival
aCox proportional hazards model included age, sex, mutation status, stage, treatment, and prior immune checkpoint blockade as covariates